drugset / Trial / NCT07446491

A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

NCT07446491 ↗

Phase 1/2 Recruiting 54 enrolled Chongqing Peg-Bio Biopharm Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

The main aim of this clinical trial is to assess the safety and efficacy of a single dose of PN20 in treatment of thrombocytopenia in adult patients with chronic liver disease undergoing an elective procedure. The main questions it aims to answer are: * How effective is PN20 in treating thrombocytopenia in patients with chronic liver disease? * Is PN20 safe in these patients? Participants will * Receive a single subcutaneous injections of PN20 or placebo according to weight before an elective procedure, * Visit the clinic for assessment.

Timeline

Start
2025-06-06
Primary completion
2026-05-30
Completion
2026-06-28

Drugs

EvaluationDrugModalityDoseRoute
Subject PN20 Peptide — Subcutaneous

Indications